Tesamorelin
FDA label for a specific indication
FDA-approved drug — specific formulations and indications
FDA approved for a specific HIV-associated lipodystrophy indication and formulation. Source: Tesamorelin — FDA prescribing information, sections 1–5 and 12.1
What it is
A growth hormone-releasing factor analog. Source: Tesamorelin — FDA prescribing information, sections 1–5 and 12.1
What it has been studied for
Excess abdominal fat in adults with HIV-associated lipodystrophy; it is not indicated for general weight loss. Source: Tesamorelin — FDA prescribing information, sections 1–5 and 12.1
Mechanism
Stimulates growth hormone release, which increases downstream IGF-1. Source: Tesamorelin — FDA prescribing information, sections 1–5 and 12.1
Documented dosing
1.28 mg · Subcutaneous — only the 11.6 mg vial formulation
Once daily
No fixed cycle in this label; continued treatment requires clinical reassessment.
Tesamorelin — FDA prescribing information, sections 1–5 and 12.1Pairings & cautions
No evidence-based peptide pairing is specified in this entry.
Contraindications include active malignancy, pregnancy and disruption of the hypothalamic-pituitary axis. Monitor glucose and IGF-1 with the prescriber. Source: Tesamorelin — FDA prescribing information, sections 1–5 and 12.1
Formulations are not interchangeable. The label gives a 0.16 mL injection volume; use the labeled preparation instructions, not a powder-mass approximation. Source: Tesamorelin — FDA prescribing information, sections 1–5 and 12.1
These are selected considerations, not a complete safety review. Discuss the full source and your medications with your prescriber.